Display Settings:

Format

Send to:

Choose Destination
Vaccine. 2011 Feb 17;29(9):1830-5. doi: 10.1016/j.vaccine.2010.12.081. Epub 2011 Jan 4.

Recombinant West Nile virus envelope protein E and domain III expressed in insect larvae protects mice against West Nile disease.

Author information

  • 1Departamento de Biotecnología, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Ctra. Coruña Km. 7.5, 28040 Madrid, Spain.

Abstract

In this study, West Nile virus (WNV) envelope (rE) protein and its domain III (rDIII) were efficiently expressed in a cost-effective system based on insect larvae as non-fermentative living biofactories. Mice immunized with the partially purified rE or rDIII elicited high antibodies titers that neutralized viral infectivity in cell culture and in suckling mice. All vaccinated animals were fully protected when challenged with neurovirulent WNV NY99. Passive transfer of protective antibodies from immunized mothers to their offspring occurred both by transplacental and lactation routes. These results indicate that the insect-derived antigens tested may constitute potential vaccine candidates to be further evaluated.

Copyright © 2010 Elsevier Ltd. All rights reserved.

PMID:
21211580
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk